Oncology FAR Biotech has quantum discoveries with validated nano-molar activity in vitro in the oncology target STAT3 – the signal transducer and activator of transcription 3, which is implicated in various human cancers.In addition, FAR Biotech is has developed quantum models in other established targets such as tumor suppressor gene p53, the focal adhesion kinase 1 (FADK1), polo-like kinase (PLK1), human epidermal growth factor receptor (Her2 kinase), mammalian target of rapamycin (mTOR), among other significant cancer targets.
Tropical Infectious Disease
Liver Stage Malaria: FAR Biotech’s technology was used to discover a novel use for a compound with known safety profile as a potential prophylactic and therapeutic against liver stage malaria. The efficacy of the compound have been confirmed in animal studies.African Sleeping Sickness: following similar path of discovery another tropical disease compound hit was discovered. The compound has a well established safety record and its novel use as sleeping sickness therapeutic has been confirmed in vitro.